Abcam, ab318335, PE Anti-Spa-1 antibody [EPR14134]

Size: 100µL
Rabbit Recombinant Monoclonal Spa-1 antibody - conjugated to PE.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14134,
Isotype:IgG,
Conjugation:PE,
Excitation/Emission:Ex: 480;565nm, Em: 578nm,
Carrier free:No,
Applications:Antibody Labelling, Target Binding AffinitySee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Spa-1 also known as human SPA plays a role in the regulation of small GTPase activity specifically targeting Rap1. This protein weighing approximately 120 kDa resides within various tissues with notable expression in the hematopoietic system and neuronal tissues. Researchers use names like Anti-SPA and Anti-Spa when referring to assays designed to recognize this protein. SPA-1 functions as a Rap1 GTPase-activating protein (GAP) facilitating the conversion of active GTP-bound Rap1 to its inactive GDP-bound form.
Biological function summary
Spa-1 engages in the control of cell adhesion and migration through its interaction with the Ras-related protein Rap1. As part of larger signal transduction complexes Spa-1 influences the organization of actin cytoskeleton and impacts integrin-mediated cell adhesion. Through its GAP activity it maintains cellular responsiveness to external stimuli impacting processes like immune cell trafficking and neuronal growth. Studies have noted its significance in maintaining homeostasis in tissues where it is expressed.
Pathways
Spa-1 integrates into key signaling cascades impacting the Ras superfamily of GTPases. Within the Rap1 signaling pathway Spa-1 works alongside proteins like RapGEF to finely regulate signal transduction processes affecting cell adhesion and cytoskeletal dynamics. In the context of the integrin signaling pathway Spa-1 modulates the actions of B-Raf in connection with Rap1 dictating responses necessary for cellular motility and positioning.
Spa-1 displays relevance to leukemia and neurological conditions. Its role in negative regulation of Rap1 activity links it to the aberrant proliferation seen in certain leukemia types where altered Rap1 signaling contributes to uncontrolled cell growth. Furthermore disruptions in Spa-1's modulation of neuronal Rap1 activity have associations with neurodegenerative diseases where proper cell migration and adhesion are impaired. Research explores its connections to proteins like BCR-ABL in the context of leukemia highlighting Spa-1 as a therapeutic target in disease management.